Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection

European Journal of Cancer Prevention

Volumn 23, Issue 3, 2014, Pages 206-224

  Asiaf, Asia ^a   Ahmad, Shiekh T ^b   Mohammad, Sheikh O ^c   Zargar, Mohammad A ^a  

^a UNIVERSITY OF KASHMIR   (India)

^b Institute for Stem Cell Biology and Regenerative Medicine   (India)

^c PONDICHERRY UNIVERSITY   (India)

Author keywords

Cervical cancer; Dysplasia; E6; E7; Human papillomavirus; Vaccine

Indexed keywords

DNA VACCINE; ORAL CONTRACEPTIVE AGENT; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS DNA; WART VIRUS VACCINE;

CANCER MORTALITY; CANCER SCREENING; DRUG EFFICACY; EPIDEMIC; HUMAN; INFECTION PREVENTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALITY; UBIQUITINATION; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; ADOLESCENT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENETICS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY; VIRUS GENOME;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOME, VIRAL; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84897452903     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328364f273     Document Type: Review

References (211)

1. American Cancer Society (2010). Human papillomavirus (HPV), cancer, and HPV vaccines-frequently asked questions: How much does the HPV vaccine cost? Is it covered by health insurance plans? Atlanta, GA: American Cancer Society. Available at: Http://www.cancer.org. [Accessed 12 May 2013].
2. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, et al. (2001). Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 184:682-690.
3. Albero G, Castellsagué X, Giuliano AR, Bosch FX (2012). Male circumcision and genital human papillomavirus: A systematic review and meta-Analysis. Sex Transm Dis 39:104.
4. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675-2686.
5. Ashrafi GH, Haghshenas M, Marchetti B, Campo MS (2006). E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 119:2105-2112.
6. Asiaf A, Ahmad ST, Zargar MA, Mufti SM, Mir SH (2012). Prevalence of human papillomavirus infection in a Kashmiri ethnic female population. Genet Test Mol Biomarkers 16:904-909.
7. Ault KA (2007). Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 369:1861-1868.
8. Bahmanyar ER, Paavonen J, Naud P, Salmeró n J, Chow SN, Apter D, et al. (2012). Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 127:440-450.
9. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR (2004). Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 31:601-607.
10. Baseman JG, Koutsky LA (2005). The epidemiology of human papillomavirus infections. J Clin Virol 32:16-24.
11. Bell MC, Schmidt-Grimminger D, Jacobsen C, Chauhan SC, Maher DM, Buchwald DS (2011). Risk factors for HPV infection among American Indian and white women in the Northern Plains. Gynecol Oncol 121:532-536.
12. Bernard HU, Calleja-Macias IE, Dunn ST (2005). Genome variation of human papillomavirus types: Phylogenetic and medical implications. Int J Cancer 118:1071-1076.
13. Bosch FX, Lorincz A, Munoz N, Meijer C, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
14. Bouvard V, Matlashewski G, Gu ZM, Storey A, Banks L (1994). The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 203:73-80.
15. Brake T, Lambert PF (2005). Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirustransgenic mouse model. Proc Natl Acad Sci USA 102:2490-2495.
16. Brown DR, Fan L, Jones J, Bryan J (1994). Colocalization of human papillomavirus type 11 E1-E4 and L1 proteins in human foreskin implants grown in athymic mice. Virology 201:46.
17. Bruni L, Diaz M, Castellsague M, Ferrer E, Bosch FX, de Sanjosé S (2010). Cervical human papillomavirus prevalence in 5 continents: Meta-Analysis of 1 million women with normal cytological findings. J Infect Dis 202: 1789-1799.
18. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee S-K, Kuypers J, et al. (1996). The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174:927-936.
19. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA (2000). Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911-1919.
20. Castellsagué X, Cohet C, Puig-Tintoré LM, Acebes LO, Salinas J, San Martin M, et al. (2009). Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health 19:106-110.
21. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105:28-37.
22. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. (2005). A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191: 1808-1816.
23. Castle PE, Schiffman M,Wheeler CM, Solomon D (2009). Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113:18.
24. Centers for Disease Control and Prevention (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 59:626-629.
25. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R (2011). Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 82:1296-1298.
26. Chen Y-H, Huang L-H, Chen T-M (1996). Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 224:651-659.
27. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE (2012). Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 30:6016-6019.
28. Chow LT, Broker TR, Steinberg BM (2010). The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 118:422-449.
29. Christensen ND, Kreider JW, Kan NC, Diangelo SL (1991). The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181:572-579.
30. Collins S, Rollason TP, Young LS,Woodman CBJ (2010). Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: A longitudinal study. Eur J Cancer 46:405-411.
31. Cotton SC, Sharp L, Seth R, Masson LF, Little J, Cruickshank ME, et al. (2007). Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer 97:133-139.
32. Cox JT, Schiffman M, Solomon D (2003). Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188:1406-1412.
33. Crook T, Tidy JA, Vousden KH (1991). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation. Cell 67:547-556.
34. Crum C, Jones C, Kirkpatrick P (2006). Quadrivalent human papillomavirus recombinant vaccine. Nat Rev Drug Discov 5:629-630.
35. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams AR (2000). A longitudinal study of HPV detection and cervical pathology in HIV infected women. Sex Transm Infect 76:257-261.
36. Cullen AP, Reid R, Campion M, Lorincz AT (1991). Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 65:606-612.
37. Cutts FT, Franceschi S, Goldie S, Castellsague X, Sanjose S, Garnett G, et al. (2007). Human papillomavirus and HPV vaccines: A review. Bull World Health Organ 85:719-726.
38. Danos O, Katinka M, Yaniv M (1982). Human papillomavirus 1a complete DNA sequence: A novel type of genome organization among papovaviridae. EMBO J 1:231-236.
39. Davies R, Hicks R, Crook T, Morris J, Vousden K (1993). Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J Virol 67:2521-2528.
40. Desai S,Wetten S,Woodhall SC, Peters L, Hughes G, Soldan K (2011). Genital warts and cost of care in England. Sex Transm Infect 87:464-468.
41. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Munoz N, Bosch FX (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-Analysis. Lancet Infect Dis 7:453-459.
42. De Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. (2010). Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056.
43. De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H (2004). Classification of papillomaviruses. Virology 324:17-27.
44. DiMaio D, Mattoon D (2001). Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 20:7866-7873.
45. Dillner J (1999). The serological response to papillomaviruses. Semin Cancer Biol 9:423-430.
46. Dillner J, Kallings I, Brihmer C, Sikstro?m B, Koskela P, Lehtinen M, et al. (1996). Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 173:1394-1398.
47. Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Koskela P, et al. (1997). Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89:1293-1299.
48. Dillner J, Arbyn M, Dillner L (2007). Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol 148: 199-207.
49. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 341:c3493.
50. Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. (2013). Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: A randomized clinical trial. JAMA 309:1793-1802.
51. Doorbar J (2006). Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 110:525-541.
52. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA (2012). The biology and life-cycle of human papillomaviruses. Vaccine 30:F55-F70.
53. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007). Prevalence of HPV infection among females in the United States. JAMA 297:813-819.
54. Dyson N (1998). The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262.
55. Dyson N, Guida P, Munger K, Harlow E (1992). Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 66:6893-6902.
56. Ebrahim SH, McKenna MT, Marks JS (2005). Sexual behaviour: Related adverse health burden in the United States. Sex Transm Infect 81:38-40.
57. Emeka EO, Ifeanyichukwu DE, Chinwendu AF, Mohammmed AB, Henry N (2012). The influence of reproductive factors on genital human papilloma virus. Internet J Gynecol Obstet 16: Doi: 10.5580/2bba.
58. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
59. Fernandes JV, Meissner R de V, de Carvalho MG, Fernandes TA, de Azevedo PR, Villa LL (2009). Prevalence of HPV infection by cervical cytologic status in Brazil. Int J Gynecol Obstet 105:21-24.
60. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ (2002). The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 277: 21730-21739.
61. Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, Lambert PF (1999). Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 262: 344-354.
62. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL, Naghavi M (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 378:1461-1484.
63. Franceschi S, Herrero R, Clifford GM, Snijders PJF, Arslan A, Anh PTH, et al. (2006). Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119:2677-2684.
64. Franco EL (1997). Understanding the epidemiology of genital infection with oncogenic and nononcogenic human papillomaviruses: A promising lead for primary prevention of cervical cancer. Cancer Epidemiol Biomarkers Prev 6:759-761.
65. Frolov MV, Dyson NJ (2004). Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 117:2173-2181.
66. Fuchs PG, Girardi F, Pfister H (2006). Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri. Int J Cancer 41:41-45.
67. Gagnon D, Joubert S, Sénéchal H, Fradet-Turcotte A, Torre S, Archambault J (2009). Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4. J Virol 83:4127-4139.
68. Ganguly N, Parihar SP (2009). Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 34:113-123.
69. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M (2010). The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40:1-13.
70. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001). Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570.
71. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. (2011a). Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 377:932-940.
72. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. (2011b). Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364:401-411.
73. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008). Costeffectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 100:308-320.
74. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96:604-615.
75. Gonzalez P, Hildesheim A, Rodríguez AC, Schiffman M, Porras C,Wacholder S, et al. (2010). Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 19:3044-3054.
76. Goodman MT, Shvetsov YB, McDuffie K,Wilkens LR, Zhu X, Ning L, et al. (2008). Acquisition of anal human papillomavirus (HPV) infection in women: The Hawaii HPV cohort study. J Infect Dis 197:957-966.
77. Greenspan D, Viliers EM, Greenspan JS, Souza YG, Hausen H (1988). Unusual HPV types in oral warts in association with HIV infection. J Oral Pathol Med 17:482-487.
78. Greenstone HL, Nieland JD, De Visser KE, De Bruijn MLH, Kirnbauer R, Roden RBS, et al. (1998). Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci 95:1800-1805.
79. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM (2012). Human papillomavirus types in 115,789 HPV-positive women: A metaanalysis from cervical infection to cancer. Int J Cancer 131:2349-2359.
80. Hamid NA, Brown C, Gaston K (2009). The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol Life Sci 66:1700-1717.
81. HeW, Staples D, Smith C, Fisher C (2003). Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol 77:10566-10574.
82. Hebner CM, Laimins LA (2006). Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16:83-97.
83. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, et al. (2005). Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191:1796-1807.
84. Hillemanns P, Breugelmans JG, Gieseking F, Bé nard S, Lamure E, Littlewood KJ, Petry KU (2008). Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study. BMC Infect Dis 8:76.
85. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E, et al. (2012). Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 19: 261-267.
86. Hines JF, Ghim SJ, Christensen ND, Kreider JW, Barnes WA, Schlegel R, Jenson AB (1994). Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol Oncol 55:13-20.
87. Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. (1995). Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365-1371.
88. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD (1998). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423-428.
89. Ho GYF, Studentsov YY, Bierman R, Burk RD (2004). Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13:110-116.
90. Ho GYF, Einstein MH, Romney SL, Kadish AS, Abadi M, Mikhail M, et al. (2011). Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: Managed by watchful waiting. J Low Genit Tract Dis 15:268-275.
91. Holowaty P, Miller AB, Rohan T, To T (1999). Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91:252-258.
92. Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, et al. (1993). Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 13:953-960.
93. Huh KW, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, et al. (2007). Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81:9737-9747.
94. Ibeanu OA (2011). Molecular pathogenesis of cervical cancer. Cancer Biol Ther 11:295-306.
95. Insinga RP, Dasbach EJ, Elbasha EH (2009). Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: A critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 9:119.
96. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. (2010). Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 19:1585-1594.
97. Jabbar SF, Park S, Schweizer J, Berard-Bergery M, Pitot HC, Lee D, Lambert PF (2012). Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein. Cancer Res 72:4008-4016.
98. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin 61:69-90.
99. Jensen KE, Schmiedel S, Frederiksen K, Norrild B, Iftner T, Kjær SK (2012). Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 21:1949-1955.
100. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, et al. (1999). The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810-5822.
101. Kashima H, Mounts P (1987). Tumors of the head and neck, larynx, lung and esophagus and their possible relation to HPV. In: Syrjaren K, Gissmann L, Koss LG, editors. Papillomaviruses and human disease. Berlin: Springer Verlag. pp. 138-157.
102. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T (1999). Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73:6188-6190.
103. Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, et al. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838-1847.
104. Kim CJ, Um SJ, Kim TY, Kim EJ, Park TC, Kim SJ, et al. (2000). Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer 10:157-164.
105. Kjaer SK, Van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, et al. (1997). Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: Are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemio Biomarkers Prev 6:799-805.
106. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, et al. (1999). Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59:6132-6136.
107. Konya J, Dillner J (2001). Immunity to oncogenic human papillomaviruses. Adv Cancer Res 82:205-238.
108. Koutsky LA, Galloway DA, Holmes KK (1988). Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10:122-163.
109. Leechanachai P, Banks L, Moreau F, Matlashewski G (1992). The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factormediated signal transduction to the nucleus. Oncogene 7:19-25.
110. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. (2012). Overall efficacy of HPV-16/18 AS04-Adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-ofstudy analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89-99.
111. Letian T, Tianyu Z (2010). Cellular receptor binding and entry of human papillomavirus. Virol J 7:2.
112. Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Eluf-Neto J, Pannuti CS (2004). Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. Gynecol Oncol 92:225-231.
113. Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, et al. (2012). Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine 13:4284-4291.
114. Liao SF, Lee WC, Chen HC, Chuang LC, Pan MH, Chen CJ (2012). Baseline human papillomavirus infection, high vaginal parity, and their interaction on cervical cancer risks after a follow-up of more than 10 years. Cancer Causes Control 23:703-708.
115. Lipari F, McGibbon GA, Wardrop E, Cordingley MG (2001). Purification and biophysical characterization of a minimal functional domain and of an Nterminal Zn2+-binding fragment from the human papillomavirus type 16 E6 protein. Biochemistry 40:1196-1204.
116. Longworth MS, Laimins LA (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362-372.
117. Maciag PC, Schlecht NF, Souza PSA, Rohan TE, Franco EL, Villa LL (2002). Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J InfectDis 186:164-172.
118. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M (2012). Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-Analysis. Lancet Infect Dis 12:781-789.
119. Manhart LE, Koutsky LA (2002). Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia: A meta-Analysis. Sex Transm Dis 29:725-735.
120. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007). Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1-24.
121. Marks M, Gravitt PE, Gupta SB, Liaw K-L, Tadesse A, Kim E, et al. (2011). Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis 204:1505-1513.
122. Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA (2009). Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 85:111-115.
123. Mathew A, George PS (2009). Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide. Asian Pac J Cancer Prev 10:645-650.
124. Maucort Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M,Wheeler CM, Schiffman M (2010). Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 126: 684-691.
125. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. (2008). HIV-1 vaccine-induced immunity in the test-of-concept step study: A case-cohort analysis. Lancet 372:1894-1905.
126. McLaughlin-Drubin ME, Munger K (2009). The human papillomavirus E7 oncoprotein. Virology 384:335-344.
127. Mendoza Plasencia Z, Gonzá lez Ló pez M, Fernández Sanfiel ML, Muniz Montes JR (2010). Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia 25:58-59.
128. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R (1989). Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 70:2227-2232.
129. Monsonego J, Breugelmans JG, Bouee S, Lafuma A, Benard S, Remy V (2007). Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynecol Obstet Fertil 35:107-113.
130. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. (2001). Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285:2995-3002.
131. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. (2004). Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364:1678-1683.
132. Moscicki AB, Schiffman M, Kjaer S, Villa LL (2006). Updating the natural history of HPV and anogenital cancer. Vaccine 24:S42-S51.
133. Moscicki AB, Ma Y,Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S (2010). Rate of and risks for regression of CIN-2 in adolescents and young women. Obstet Gynecol 116:1373-1380.
134. Munoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
135. Munoz N, Fn Mendez, Hc Posso, Mn Molano, van den Brule AJC, Ronderos M, et al. (2004). Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190:2077-2087.
136. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M,Wheeler CM, et al. (2010). Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-Associated genital diseases in young women. J Natl Cancer Inst 102:325-339.
137. Narisawa-Saito M, Kiyono T (2007). Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 98:1505-1511.
138. Nasiell K, Nasiell M, Vać lavinková V (1983). Behavior of moderate cervical dysplasia during long-Term follow-up. Obstet Gynecol 61:609-614.
139. Nguyen CL, Munger K (2008). Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 380: 21-25.
140. Niedergang F, Didierlaurent A, Kraehenbuhl J-P, Sirard J-C (2004). Dendritic cells: The host Achille's heel for mucosal pathogens? Trends Microbiol 12:79-88.
141. Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, et al. (2012). Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: Community based cohort study. BMJ 344:e4168.
142. Ostor AG (1993). Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 12:186-192.
143. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM (2001). Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 183:383-391.
144. Palefsky JM, Gillison ML, Strickler HD (2006). HPV vaccines in immunocompromised women and men. Vaccine 24:S140-S146.
145. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. (2011). HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576-1585.
146. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros M (2008). Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 26: L1-L15.
147. Pater MM, Mittal R, Pater A (1994). Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol 2:229-235.
148. Patrick DR, Oliff A, Heimbrook DC (1994). Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J Biol Chem 269:6842-6850.
149. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S (2010). Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 86:181-186.
150. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D,Wheeler CM (2007). A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 195:1582-1589.
151. Repp KK, Nielson CM, Fu R, Schafer S, Lazcano-Ponce E, Salmerón J, et al. (2012). Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis 205:1287-1293.
152. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P (2000). Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis 27:79-86.
153. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al. (2003). The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12:485-490.
154. Richardson H, Abrahamowicz M, Tellier P-P, Kelsall G, du Berger R, Ferenczy A, et al. (2005). Modifiable risk factors associated with clearance of typespecific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 14:1149-1156.
155. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT (1996). Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70:3298-3301.
156. Roden R, Yutzy WH IV, Fallon R, Inglis S, Lowy DR, Schiller JT (2000). Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270:254-257.
157. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. (2008). Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513-517.
158. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. (2012). Sustained immunogenicity and efficacy of the HPV-16/18 AS04-Adjuvanted vaccine: Up to 8.4 years of follow-up. Hum Vaccin Immunother 8:390-397.
159. Schabath MB, Villa LL, Lazcano-Ponce E, Salmeró n J, Quiterio M, Giuliano AR (2012). Smoking and human papillomavirus (HPV) infection in the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev 21:102-110.
160. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
161. Schiffman M, Castle PE, Maucort-Boulch D,Wheeler CM, Plummer M (2007). A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 195:1582-1589.
162. Schiller JT, Davies P (2004). Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2:343-347.
163. Schiller JT, Castellsagué X, Villa LL, Hildesheim A (2008). An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26:K53-K61.
164. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A,Villa LL, Franco EL (2002). Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 103:519-524.
165. Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. (2000). Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Can Med Assoc J 163:503-508.
166. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, et al. (2003). Incidence, clearance and predictors of human papillomavirus infection in women. Can Med Assoc J 168:421-425.
167. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW (1997). Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 6:233-237.
168. Shai A, Brake T, Somoza C, Lambert PF (2007). The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 67:1626-1635.
169. Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR (2006). Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 160:151-156.
170. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
171. Simen-Kapeu A, Kataja V, Yliskoski M, Syrjanen K, Dillner J, Koskela P, et al. (2008). Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand J Infect Dis 40:745-751.
172. Smith JS, Melendy A, Rana RK, Pimenta JM (2008). Age-specific prevalence of infection with human papillomavirus in females: A global review. J Adolesc Health 43:S5-S25, S25.e1-S25.e41.
173. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM (2011). Age-specific prevalence of human papillomavirus infection in males: A global review. J Adolesc Health 48:540-552.
174. Stern PL (2004). Recent developments in human papillomavirus vaccines. Expert Opin Investig Drugs 13:959-971.
175. Stoppler MC, Straight SW, Tsao G, Schlegel R, McCance DJ (1996). The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 223:251-254.
176. Stubenrauch F, Laimins LA (1999). Human papillomavirus life cycle: Active and latent phases. Semin Cancer Biol 379-386.
177. Sycuro LK, Xi LF, Hughes JP, Feng Q, Winer RL, Lee S-K, et al. (2008). Persistence of genital human papillomavirus infection in a long-Term follow-up study of female university students. J Infect Dis 198:971-978.
178. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S (1992). Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 79 (Pt 1):675-682.
179. Syrjanen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, et al. (2007). Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN. Eur J Epidemiol 22:723-735.
180. Syrjanen KJ (2002). HPV infections and oesophageal cancer. J Clin Pathol 55:721-728.
181. Syrjanen SM, Syrjanen KJ (1999). New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med 31:175-187.
182. Teixeira NCP, Araú jo ACL, Correa CM, Lodi CTC, Lima MIM, Carvalho NO, et al. (2012). Prevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women. Braz J Infect Dis 16:164-169.
183. Thomas M, Banks L (1998). Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17:2943-2954.
184. Tobian AAR, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. (2009). Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 360:1298-1309.
185. Tobian AAR, Gray RH, Quinn TC (2010). Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: The case for neonatal circumcision. Arch Pediatr Adolesc Med 164:78-84.
186. Trottier H, Franco EL (2006). The epidemiology of genital human papillomavirus infection. Vaccine 24:S4-S15.
187. Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, et al. (2008). Type-specific duration of human papillomavirus infection: Implications for human papillomavirus screening and vaccination. J Infect Dis 197:1436-1447.
188. Tsai TC, Chen SL (2003). The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch Virol 148:1445-1453.
189. Vaccarella S, Herrero R, Snijders PJF, Dai M, Thomas JO, Hieu NT, et al. (2008). Smoking and human papillomavirus infection: Pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 37:536-546.
190. Valle GF, Banks L (1995). The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol 76:1239-1245.
191. Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, Andrade RP, et al. (2006a). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24:5571-5583.
192. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. (2006b). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459-1466.
193. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, et al. (2004). Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13:324-327.
194. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM (2000). International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 86:429-435.
195. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
196. Wanichwatanadecha P, Sirisrimangkorn S, Kaewprag J, Ponglikitmongkol M (2012). Transactivation activity of human papillomavirus type 16 E6 I on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells. J Gen Virol 93 (Pt 5):1081-1092.
197. Wawer MJ, Tobian AAR, Kigozi G, Kong X, Gravitt PE, Serwadda D, et al. (2011). Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: A randomised trial in Rakai, Uganda. Lancet 377:209-218.
198. White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim S-j, Hewitt LA, et al. (1999). Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73:4882-4889.
199. WHO/ICO (2010). Information centre on HPV and cervical cancer (HPV information centre). Human papillomavirus and related cancers in world. Summary Report HPV related statistics. Available at: Http://www.who.int/hpvcentre. [Accessed 25 November 2012].
200. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, et al. (1995). Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 172:1425-1430.
201. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA (2003). Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 157:218-226.
202. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA (2006). Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354:2645-2654.
203. Wise-Draper TM, Wells SI (2008). Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci 13:1003-1017.
204. Wu EW, Clemens KE, Heck DV, Munger K (1993). The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol 67:2402-2407.
205. Yim EK, Park JS (2005). The role of HPV E6 and E7 oncoproteins in HPVassociated cervical carcinogenesis. Cancer Res Treat 37:319-324.
206. Ylitalo N, Sørensen P, Josefsson AM, PKE Magnusson, Andersen PK, Pontén J, et al. (2000). Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 355: 2194-2198.
207. Yoon CS, Kim KD, Park SN, Cheong SW (2001). Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem Biophys Res Commun 283:668-673.
208. Zhang YX, Xiong Y, Gui XE, Rong YP, Cai HB, Ma L (2012). Analysis of cervical HPV infection in HIV positive Chinese women. Zhonghua Fu Chan Ke Za Zhi 47:185.
209. Zur Hausen H (1989). Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 49: 4677-4681.
210. Zur Hausen H (1991). Viruses in human cancers. Science 254:1167-1673.
211. Zur Hausen H (1996). Papillomavirus infections-A major cause of human cancers. Biochim Biophys Acta 1288:F55-F78.